Abstract
Phenylketonuria (PKU; OMIM 261600), the most common disorder of amino acid metabolism, is caused by a deficient activity of human phenylalanine hydroxylase (hPAH). Although the dietetic treatment has proven to be effective in preventing the psycho-motor impairment, much effort has been made to develop new therapeutic approaches. Enzyme replacement therapy with hPAH could be regarded as a potential form of PKU treatment if the reported in vitro hPAH instability could be overcome. In this study, we investigated the effect of different polyol compounds, e.g. glycerol, mannitol and PEG-6000 on the in vitro stability of purified hPAH produced in a heterologous prokaryotic expression system. The recombinant human enzyme was stored in the presence of the studied stabilizing agents at different temperatures (4 and −20 °C) during a 1-month period. Protein content, degradation products, specific activity, oligomeric profile and conformational characteristics were assessed during storage. The obtained results showed that the use of 50% glycerol or 10% mannitol, at −20 °C, protected the enzyme from loss of its enzymatic activity. The determined ΔG 0 and quenching parameters indicate the occurrence of conformational changes, which may be responsible for the observed increase in catalytic efficiency.
Similar content being viewed by others
References
Lichter-Konecki, U., Hipke, C. M., & Konecki, D. S. (1999). Molecular Genetics and Metabolism, 67, 308–316.
Moller, N., Meek, S., Bigelow, M., Andrews, J., & Nair, K. S. (2000). Proceedings of National Academy of Sciences USA, 97, 1242–1246.
Scriver, C. R. (2007). Human Mutation, 28, 831–845.
Surtees, R., & Blau, N. (2000). European Journal of Pediatrics, 159(Suppl 2), S109–S113.
(1993). Arch Dis Child, 68, 426–427.
(2001). Pediatrics, 108, 972–982.
de Freitas, O., Izumi, C., Lara, M. G., & Greene, L. J. (1999). Nutrition Reviews, 57, 65–70.
Widaman, K. F., & Azen, C. (2003). Pediatrics, 112, 1537–1543.
Kure, S., Hou, D. C., Ohura, T., Iwamoto, H., Suzuki, S., Sugiyama, N., et al. (1999). Journal of Pediatrics, 135, 375–378.
Blau, N., & Erlandsen, H. (2004). Molecular Genetics and Metabolism, 82, 101–111.
Sarkissian, C. N., Shao, Z., Blain, F., Peevers, R., Su, H., Heft, R., et al. (1999). Proceedings of National Academy of Sciences USA, 96, 2339–2344.
Gamez, A., Sarkissian, C. N., Wang, L., Kim, W., Straub, M., Patch, M. G., et al. (2005). Molecular Therapeutic, 11, 986–989.
Sarkissian, C. N., & Gamez, A. (2005). Molecular Genetics and Metabolism, 86(Suppl 1), S22–S26.
Flatmark, T., & Stevens, R. C. (1999). Chemical Reviews, 99, 2137–2160.
Thorolfsson, M., Ibarra-Molero, B., Fojan, P., Petersen, S. B., Sanchez-Ruiz, J. M., & Martinez, A. (2002). Biochemistry, 41, 7573–7585.
Frokjaer, S., & Otzen, D. E. (2005). Nature Reviews Drug Discovery, 4, 298–306.
Crommelin, D. J., Storm, G., Verrijk, R., de Leede, L., Jiskoot, W., & Hennink, W. E. (2003). International Journal of Pharmaceutics, 266, 3–16.
Wang, W. (1999). International Journal of Pharmaceutics, 185, 129–188.
Gamez, A., Wang, L., Straub, M., Patch, M. G., & Stevens, R. C. (2004). Molecular Therapeutic, 9, 124–129.
Kwok, S. C., Ledley, F. D., DiLella, A. G., Robson, K. J., & Woo, S. L. (1985). Biochemistry, 24, 556–561.
Leandro, P., Rivera, I., Lechner, M. C., de Almeida, I. T., & Konecki, D. (2000). Molecular Genetics and Metabolism, 69, 204–212.
Bradford, M. M. (1976). Analytical Biochemistry, 72, 248–254.
Kaufman, S. (1987). Methods in Enzymology, 142, 3–17.
Kleppe, R., Uhlemann, K., Knappskog, P. M., & Haavik, J. (1999). Journal of Biological Chemistry, 274, 33251–33258.
Pace, C. N. (1986). Methods in Enzymology, 131, 266–280.
Knappskog, P. M., & Haavik, J. (1995). Biochemistry, 34, 11790–11799.
Lehrer, S. S. (1971). Biochemistry, 10, 3254–3263.
Knappskog, P. M., Flatmark, T., Aarden, J. M., Haavik, J., & Martinez, A. (1996). European Journal of Biochemistry, 242, 813–821.
Kaufman, S. (1993). Advances in Enzymology and Related Areas of Molecular Biology, 67, 77–264.
Woo, S. L., Gillam, S. S., & Woolf, L. I. (1974). Biochemical Journal, 139, 741–749.
Chang, N., Kaufman, S., & Milstien, S. (1979). Journal of Biological Chemistry, 254, 2665–2668.
Wang, W. (2000). International journal of pharmaceutics, 203, 1–60.
Powell, M. F. (1996). In R. Pearlman & Y. J. Wang (Eds.), Formulation, characterization and stability of protein drugs (pp. 1–140). New York: Plenum Press.
Shulgin, I. L., & Ruckenstein, E. (2006). Biophysical Chemistry, 120, 188–198.
Pey, A. L., Desviat, L. R., Gamez, A., Ugarte, M., & Perez, B. (2003). Human Mutation, 21, 370–378.
Bjorgo, E., de Carvalho, R. M., & Flatmark, T. (2001). European Journal of Biochemistry, 268, 997–1005.
Shiman, R., Gray, D. W., & Pater, A. (1979). Journal of Biological Chemistry, 254, 11300–11306.
Andersen, O. A., Flatmark, T., & Hough, E. (2002). Journal of Molecular Biology, 320, 1095–1108.
Stokka, A. J., Carvalho, R. N., Barroso, J. F., & Flatmark, T. (2004). Journal of Biological Chemistry, 279, 26571–26580.
Timasheff, S. N. (1998). Advances in Protein Chemistry, 51, 355–432.
Bolen, D. W., & Baskakov, I. V. (2001). Journal of Molecular Biology, 310, 955–963.
Barteri, M., Gaudiano, M. C., & Santucci, R. (1996). Biochimica et Biophysica Acta, 1295, 51–58.
Lino, P. R., Almeida, A. J., de Tavares, A. I., & Leandro, P. (2009). FEBS Journal, 276, 323.
Acknowledgements
This work was supported by Fundação para a Ciência e Tecnologia, Portugal, and FEDER: Project PTDC/QUI/64023/2006 and Grants SFRH/BD/10807/2002 (to Cátia Nascimento) and SFRH/BD/19024/2004 (to João Leandro).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nascimento, C., Leandro, J., Lino, P.R. et al. Polyol Additives Modulate the In Vitro Stability and Activity of Recombinant Human Phenylalanine Hydroxylase. Appl Biochem Biotechnol 162, 192–207 (2010). https://doi.org/10.1007/s12010-009-8862-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12010-009-8862-y